Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy
about
Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumorsCabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experiencePrognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.Development of a realistic in vivo bone metastasis model of human renal cell carcinomaSites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib.HIF targets in bone remodeling and metastatic disease.Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy.Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective AnalysisBody Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results.Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIsRenal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis.C-met inhibition blocks bone metastasis development induced by renal cancer stem cells.Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study.Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.Current management and future perspectives of metastatic renal cell carcinoma.Landmarks in the diagnosis and treatment of renal cell carcinoma.Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma.Clinical correlates and prognostic value of different metastatic sites in metastatic renal cell carcinoma.Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents.Cabozantinib for the treatment of kidney cancer.Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.Surgical Management of Renal Cell Cancer Liver Metastases.Impact of neutrophil-to-lymphocyte ratio on effects of targeted therapy for metastatic renal cell carcinoma patients with extrapulmonary metastasis.Cabozantinib for the treatment of renal cell carcinoma.Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor.Comprehensive analysis and validation of contemporary survival prognosticators in Korean patients with metastatic renal cell carcinoma treated with targeted therapy: prognostic impact of pretreatment neutrophil-to-lymphocyte ratio.Spinal metastasectomy of renal cell carcinoma: A 16-year single center experience with a minimum 3-year follow-up.The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis.Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival?Third-line treatment in metastatic renal cell carcinoma and bone metastases.Outcomes of Patients With Late-Relapse Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Single Institution Experience.Inherent characteristics of metachronous metastatic renal cell carcinoma in the era of targeted agents.Multimodal treatment of advanced renal cancer in 2017.Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal.Role of RPLND and Metastasectomy in the Management of Oligometastatic Renal Cell Carcinoma.Is there always a need for invasive treatment of limited liver metastases in renal cell cancer or other solid tumors?Metastasis in renal cell carcinoma: Biology and implications for therapy.
P2860
Q26799046-55D8C681-9F2D-41AC-BFC7-7BF50A94A3A4Q28072166-7A7FCA10-CC27-40D0-9DE6-47318ABCF555Q34090594-3EA9BA71-A3FC-4590-80C4-26D802CC6698Q35154534-F439329C-316E-4B98-8630-7DDE96B0F331Q35214229-96C6B6C3-954E-4664-AE64-7F8EAE2799FCQ35554344-786FB51F-40BA-43DE-B2AF-ADA05B82474CQ35674216-BB9AC926-3D37-4040-B8FE-D8EF945FA6E3Q35985736-CC21BCBA-6618-4882-8909-4F6E486615A7Q36124825-A81B7E51-E2FD-4964-BE29-717CED135373Q36281483-DFF89EA6-CAB6-470A-8E0F-4219C6171746Q36287386-ED3793B3-256A-4C19-B9B9-4651AB775253Q36372611-3E5CBE0F-F86B-440F-86CB-A3DFCD0006BCQ36750660-BAA32443-5651-450D-BC76-9E29B4B928D5Q37253841-0041E6AF-B974-4DA8-9697-459F8B5ED1AFQ37564471-260D2D96-7021-4665-BA8C-D35FD137C9ABQ37657236-80035711-20C4-4B17-93B4-25161E502C7EQ37672483-8ADB521A-77A2-4359-8FEE-4EB7B4180BE7Q38214976-67C341BD-2433-45AF-A650-F835B6D3A621Q38238966-920D1E24-657E-439A-84CE-3E01C6E10D53Q38543085-739A8BEA-9E37-44D9-9D85-D11E1B5B4FE2Q38610752-65775524-FF4F-4778-8490-558C57F4B04CQ38624864-BD317B7D-69F1-4767-AFD5-9F75060DD2B2Q38668871-17A94006-954E-43AE-B1B5-E27377E6E334Q38746778-23A64929-EE7C-43EE-BC6A-CFFB30A2A62EQ38756058-0690054C-ABE5-4294-9F43-C86E93CA046AQ38786760-3CDE2C3D-C4C9-4D6C-AB6A-C325F1256062Q39005403-B49AC62A-E76A-4AAE-865F-3B56812D0E60Q39155548-5AD693AD-AB39-477B-AAEE-623B06FC8B4CQ39945553-865561E0-35E1-4139-9642-E0FDEB5D288EQ40929096-7352F993-15E7-4D21-B729-253DE9C6E895Q41036577-B37A5AC0-554C-46BC-881D-8D0BA1642AECQ41111225-B7A397E6-74E3-48D7-862A-6447D7011A6AQ42160662-7525CF85-6829-4981-A8C6-A34CA06ED3AAQ47149978-2732EAA4-3F09-4F99-9F96-EB17D1019573Q47158686-3AA41808-0CFA-4361-AE55-04F993880BC6Q47550490-0E763BFC-AAAC-4B5C-B987-29819F7D5D31Q52321029-71D7876C-F8E3-4A81-8EA9-3B64F60472FEQ52643813-DE1E0B29-5710-4BB6-A33C-5ED7AA2E1A35Q53064304-EA3792AD-866C-45ED-A72F-561953203610Q54936635-D9B71763-9688-4E06-B078-48C0EC7D8E7B
P2860
Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Impact of bone and liver metas ...... treated with targeted therapy
@ast
Impact of bone and liver metas ...... treated with targeted therapy
@en
Impact of bone and liver metas ...... treated with targeted therapy
@nl
type
label
Impact of bone and liver metas ...... treated with targeted therapy
@ast
Impact of bone and liver metas ...... treated with targeted therapy
@en
Impact of bone and liver metas ...... treated with targeted therapy
@nl
prefLabel
Impact of bone and liver metas ...... treated with targeted therapy
@ast
Impact of bone and liver metas ...... treated with targeted therapy
@en
Impact of bone and liver metas ...... treated with targeted therapy
@nl
P2093
P2860
P50
P1433
P1476
Impact of bone and liver metas ...... treated with targeted therapy
@en
P2093
Brian I Rini
Daniel Y C Heng
Jae-Lyun Lee
Jennifer J Knox
Mary J MacKenzie
Nils Kroeger
Rana R McKay
Sandy Srinivas
Srinivas K Tantravahi
P2860
P304
P356
10.1016/J.EURURO.2013.08.012
P407
P577
2013-08-15T00:00:00Z